Skip to content
PeptideFactSheets
FDA approved for specific usesStrong human evidence for approved uses

Plain-English fact sheet

Tirzepatide

Also known as Mounjaro, Zepbound

Weight managementMetabolic healthHeart and kidney outcomes

Tirzepatide is a peptide-based medicine with strong human evidence for specific FDA-approved uses, including type 2 diabetes and chronic weight management.

Quick answer

Tirzepatide is FDA approved in specific prescription products and populations. Zepbound also has an FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity.

By the PeptideFactSheets Editorial Team. Use the source links to verify status, evidence, risks, and unknowns; our editorial policyexplains the boundaries. Clinician review appears only when a named reviewer is shown.

What is Tirzepatide?

Tirzepatide is a manufactured medicine that activates two receptors involved in metabolic signaling: GIP and GLP-1.

Mounjaro and Zepbound contain the same active ingredient but have distinct FDA-labeled uses.

Why are people interested in it?

Interest centers on blood-sugar control, body-weight outcomes, and the obstructive-sleep-apnea indication.

It is also being studied for cardiovascular, kidney, and liver outcomes.

Current regulatory status

FDA approved for specific uses

Tirzepatide products are FDA approved for specific uses, including type 2 diabetes, chronic weight management, and—under the Zepbound label—moderate-to-severe obstructive sleep apnea in adults with obesity.

What is it approved for?

  • Improving blood sugar control in specified people with type 2 diabetes
  • Chronic weight management in specified adults
  • Moderate-to-severe obstructive sleep apnea in adults with obesity under the Zepbound label

FDA approval path

FDA approved

FDA approved for product-specific uses

Mounjaro and Zepbound have FDA-approved indications, including diabetes, chronic weight management, and the Zepbound obstructive-sleep-apnea indication. The approval does not extend to every metabolic claim.

Step 7 of 7

  1. DiscoveryBasic research
  2. PreclinicalLab and animal work
  3. Phase 1Initial human testing
  4. Phase 2Condition-focused trials
  5. Phase 3Confirmatory trials
  6. FDA reviewApplication review
  7. ApprovedLabel-specific use

Timeline source basis

FDA prescribing information: MounjaroFDA prescribing information: ZepboundFDA: first medication approved for obstructive sleep apnea

What is it being studied for?

Type 2 diabetes
Chronic weight management
Obstructive sleep apnea in adults with obesity
Cardiovascular and kidney outcomes
Metabolic liver disease

Investigational areas

  • Additional cardiovascular, kidney, and liver outcomes
  • Other uses not listed in a current product label

Evidence snapshot

Strong human evidence for approved uses

Large randomized trials support approved indications. Results cannot be assumed to apply to unstudied populations, products, or claims.

Potential benefits being researched

  • Trials supporting approved labels found benefits in their specified metabolic and sleep-apnea outcomes.
  • Additional outcome studies may clarify where benefits extend beyond current labels.

Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.

Known or possible risks

  • Common effects include nausea, diarrhea, vomiting, constipation, abdominal discomfort, and other gastrointestinal symptoms.
  • Current labeling includes a boxed warning about thyroid C-cell tumors in rats and important contraindications.
  • Other labeled concerns include pancreatitis, gallbladder problems, kidney injury, hypoglycemia with certain medicines, and aspiration risk around anesthesia or deep sedation.

What we still do not know

  • Outcomes for uses and populations not yet studied in large trials
  • Very long-term outcomes across increasingly broad populations
  • Whether every ongoing outcome trial will confirm early signals
  • Quality and safety of products marketed outside approved supply chains

Related research updates

FDA approves tirzepatide for obstructive sleep apnea in adults with obesityRetatrutide Phase 3 program reports top-line results

Plain-English takeaway

Tirzepatide has strong evidence for specific approved uses, but brand, indication, eligibility, contraindications, and clinical oversight all matter.

Research and reference links

Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.

  1. 1
    fdaFDA prescribing information: Mounjaro

    Official tirzepatide prescribing information for a type 2 diabetes product.

  2. 2
    fdaFDA prescribing information: Zepbound

    Official tirzepatide prescribing information for chronic weight management and obstructive-sleep-apnea indications.

  3. 3
    fdaFDA: first medication approved for obstructive sleep apnea

    FDA announcement of the Zepbound obstructive-sleep-apnea indication.

  4. 4
    clinical trialsClinicalTrials.gov: SURMOUNT-1 tirzepatide trial

    Registry record for a pivotal tirzepatide chronic-weight-management trial.

  5. 5
    pubmedSURMOUNT-1 tirzepatide randomized trial

    Peer-reviewed report of tirzepatide in adults with obesity.